BPG is committed to discovery and dissemination of knowledge
Retrospective Study
©The Author(s) 2026.
World J Diabetes. Feb 15, 2026; 17(2): 112859
Published online Feb 15, 2026. doi: 10.4239/wjd.v17.i2.112859
Figure 5
Figure 5 Nomogram model and results of decision curve analysis for quantifying the individual risk of diabetic gastric autonomic neuropathy in patients with type 2 diabetes mellitus. A: The nomogram includes age, fasting C-peptide, and taurolithocholic acid along with their corresponding points and total risk scores; B: Decision curve analysis was performed to evaluate the clinical net benefit across different risk thresholds. TLCA: Taurolithocholic acid; FC-P: Fasting C-peptide; DGAN: Diabetic gastric autonomic neuropathy.


Write to the Help Desk